<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564146</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-PAK-0114</org_study_id>
    <secondary_id>2014-004086-24</secondary_id>
    <secondary_id>AX-CL-PANC-AIO-004415</secondary_id>
    <nct_id>NCT02564146</nct_id>
  </id_info>
  <brief_title>First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine</brief_title>
  <acronym>ALPACA</acronym>
  <official_title>Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALPACA is an interventional, multicentre, open-label, randomized active-controlled phase II&#xD;
      trial with two arms.&#xD;
&#xD;
      To estimate the treatment effect on overall survival, feasibility, efficacy and safety of&#xD;
      alternating treatment cycles of gemcitabine monotherapy followed by&#xD;
      nab-paclitaxel/gemcitabine relative to standard continuing nab-paclitaxel/gemcitabine cycles&#xD;
      in first-line treatment for metastatic pancreatic cancer in patients having received 3 cycles&#xD;
      of induction therapy with standard nab-paclitaxel/gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALPACA is an interventional, multicentre, open-label, randomized active-controlled phase II&#xD;
      trial with two arms.&#xD;
&#xD;
      To estimate the treatment effect on overall survival, feasibility, efficacy and safety of&#xD;
      alternating treatment cycles of gemcitabine monotherapy followed by&#xD;
      nab-paclitaxel/gemcitabine relative to standard continuing nab-paclitaxel/gemcitabine cycles&#xD;
      in first-line treatment for metastatic pancreatic cancer in patients having received 3 cycles&#xD;
      of induction therapy with standard nab-paclitaxel/gemcitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>After randomization until date of death or end of study wichever comes first. Assessed for up to 38.5 month</time_frame>
    <description>To estimate the treatment effect of alternating treatment cycles of gemcitabine monotherapy followed by nab-paclitaxel/gemcitabine relative to standard continuing nab-paclitaxel/gemcitabine treatment cycles in first-line treatment for metastatic pancreatic cancer in patients having received 3 cycles of induction therapy with standard nab-paclitaxel/gemcitabine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3.5 month</time_frame>
    <description>During induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>42 month</time_frame>
    <description>Determined from first application of induction treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3.5 month</time_frame>
    <description>During induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Assessed for up to 38.5 month</time_frame>
    <description>As time from randomization to objective tumor progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Assessed for up to 42 month</time_frame>
    <description>As time from randomization to objective tumor progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Assessed for up to 42 month</time_frame>
    <description>According to RECISTv1.1 determined from first application of induction treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Assessed for up to 3.5 month</time_frame>
    <description>During induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Assessed for up to 42 month</time_frame>
    <description>According to RECISTv1.1 determined from first application of induction treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Assessed for up to 3.5 month</time_frame>
    <description>During induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life QLQ-C30</measure>
    <time_frame>Assessed for up to 3.5 month</time_frame>
    <description>During induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life QLQ-C30</measure>
    <time_frame>Assessed for up to 8 month</time_frame>
    <description>As determined with EORTC QLQ-C30 determined from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>Assessed for up to 11.5 month</time_frame>
    <description>Type, incidence, and severity according to NCI CTCAE version 4 with explicit consideration of any neurotoxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>Assessed for up to 3.5 month</time_frame>
    <description>Type, incidence, and severity according to NCI CTCAE version 4 with explicit consideration of any neurotoxicity during induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of treatment without toxicity</measure>
    <time_frame>Assessed for up to 11.5 month</time_frame>
    <description>Duration of treatment without toxicity leading to permanent discontinuation during induction and randomized phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of treatment without toxicity</measure>
    <time_frame>Assessed for up to 3.5 month</time_frame>
    <description>Duration of treatment during induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotoxicity Assessment FACT taxane score</measure>
    <time_frame>Assessed for up to 11.5 month</time_frame>
    <description>Functional assessment of neurotoxicity (with FACT taxane score) during induction and randomized phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotoxicity Assessment FACT taxane score</measure>
    <time_frame>Assessed for up to 3.5 month</time_frame>
    <description>Functional assessment of neurotoxicity (with FACT taxane score) during induction phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">325</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel and gemcitabine (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction treatment: 3 cycles nab-paclitaxel and gemcitabine&#xD;
Continuous treatment after randomization: Continuing application of nab-paclitaxel and gemcitabine treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment: 3 cycles nab-paclitaxel and gemcitabine&#xD;
Continuous treatment after randomization: alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel and gemcitabine</intervention_name>
    <description>Induction treatment:&#xD;
3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.&#xD;
Continouous treatment after randomization:&#xD;
Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.</description>
    <arm_group_label>gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)</arm_group_label>
    <arm_group_label>nab-paclitaxel and gemcitabine (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine mono and nab-paclitaxel and gemcitabine</intervention_name>
    <description>Induction treatment:&#xD;
3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.&#xD;
Continouous treatment after randomization:&#xD;
Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.&#xD;
Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.&#xD;
Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.&#xD;
Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.</description>
    <arm_group_label>gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥ 18 years of age)&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.&#xD;
             Patients with islet cell neoplasms are excluded.&#xD;
&#xD;
          -  Karnofsky Perfomance Status (KPS) ≥ 70%&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion as assessed by CT- scan or Magnetic&#xD;
             resonance imaging (MRI) according to Response Evaluation Criteria In Solid Tumors&#xD;
             (RECIST1.1 ),&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN (Upper Limit of Normal). Patients with a biliary stent may&#xD;
             be included provided that bilirubin level after stent insertion decreased to ≤ 1.5 x&#xD;
             ULN and there is no cholangitis.&#xD;
&#xD;
          -  Adequate renal, hepatic and bone marrow function, defined as&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 mL/min according to CKD-EPI formula (Chronic&#xD;
                  kidney Disease Epidemiology Collaboration)&#xD;
&#xD;
               -  AST/GOT and/or ALT/GPT ≤ 2.5 x ULN and ≤ 5.0 x ULN in case of liver metastasis&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Haemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Platelets ≥ 100 x 100 x 10^9/L&#xD;
&#xD;
          -  Females of Childbearing Potential (FCBP) must have a negative serum pregnancy test&#xD;
             within 7 days of the first application of study treatment and they must agree to&#xD;
             undergo further pregnancy tests before randomization and at the end of treatment visit&#xD;
             and&#xD;
&#xD;
          -  FCBP must either agree to use and be able to take effective contraceptive birth&#xD;
             control measures (Pearl Index &lt; 1) or agree to practice complete abstinence from&#xD;
             heterosexual intercourse during the course of the study and for at least 1 month after&#xD;
             last application of study treatment. A female subject is considered to be of&#xD;
             childbearing potential unless she is age ≥ 50 years and naturally amenorrhoeic for ≥ 2&#xD;
             years, or unless she is surgically sterile.&#xD;
&#xD;
          -  Males must agree not to father a child during the course of the trial and for at least&#xD;
             6 months after last administration of study drugs.&#xD;
&#xD;
          -  Signed and dated informed consent before the start of any specific protocol procedures&#xD;
             Patient's legal capacity to consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing histological or cytological confirmation of metastatic adenocarcinoma of the&#xD;
             pancreas Locally advanced pancreatic adenocarcinoma without metastases Any previous&#xD;
             radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of&#xD;
             metastatic disease. (Prior adjuvant chemotherapy with gemcitabine or fluoropyrimidine&#xD;
             in curative intent is allowed if terminated more than 6 months before first&#xD;
             application of study treatment. Previous palliative radiotherapy of bonemetastases for&#xD;
             alleviation of pain is permitted provided that irradiated bone metastases are no&#xD;
             target lesions.) Known brain metastase/brain metastases. Brain imaging is required in&#xD;
             symptomatic patients to rule out brain metastases, but is not required in asymptomatic&#xD;
             patients.&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy ≥ grade 2 according to CTCAE version 4 (Common&#xD;
             Terminology Criteria for Adverse Events)&#xD;
&#xD;
          -  • Medical history of interstitial lung disease (ILD) or pulmonary fibrosis&#xD;
&#xD;
          -  Patients with high cardiovascular risk, including, but not limited to, recent coronary&#xD;
             stenting or myocardial infarction in the past year.&#xD;
&#xD;
          -  Uncontrolled severe illness or medical condition (including uncontrolled diabetes&#xD;
             mellitus)&#xD;
&#xD;
          -  Any other severe concomitant disease or disorder, which could influence patient's&#xD;
             ability to participate in the study and his/her safety during the study or interfere&#xD;
             with interpretation of study results e.g. severe hepatic, renal, pulmonary, metabolic,&#xD;
             or psychiatric disorders Previous or concurrent tumor other than underlying tumor&#xD;
             disease (pancreatic cancer) with the exception of cervical cancer in situ, adequately&#xD;
             treated basal cell carcinoma or squamous cell carcinoma of the skin, superficial&#xD;
             bladder tumors (Ta, Tis, and T1) or any curatively treated tumors &gt; 5 years prior to&#xD;
             enrolment Hypersensitivity against nab-paclitaxel, gemcitabine, or any excipients of&#xD;
             these drugs&#xD;
&#xD;
          -  Continuing abuse of alcohol, drugs, or medical drugs&#xD;
&#xD;
          -  Pregnant females, breast feeding females or females of childbearing potential unable&#xD;
             to perform adequate contraceptive measures or practice complete abstinence from&#xD;
             heterosexual intercourse&#xD;
&#xD;
          -  Participation in any other clinical trial or treatment with any experimental drug&#xD;
             within 28 days before enrolment to the study or during study participation until the&#xD;
             end of treatment visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Kullmann, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kliniken Nordoberpfalz AG Klinikum Weiden Medizinische Kliniken I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kliniken Nordoberpfalz AG, Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

